ZimVie Inc. has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED, a healthcare-focused investment firm, the company announced on July 21, 2025. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock. According to the company, the transaction represents an enterprise value of approximately $730 million and a 99 percent premium to ZimVie’s 90-day volume-weighted average price of $9.57 per share.
“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,” said Vafa Jamali, chairman of the board and chief executive officer of ZimVie. “Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”
“We’re excited to partner with ZimVie and its talented team,” said André-Michel Ballester, managing partner at ARCHIMED. “The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”
According to the company, the transaction has been unanimously approved by ZimVie’s Board of Directors and is expected to close by the end of 2025, pending approval by ZimVie stockholders and customary regulatory approvals. The deal is not subject to a financing condition. Until the closing is finalized, ZimVie will continue operating independently.
Upon completion of the transaction, ZimVie will become a privately held company and its shares will be delisted from the NASDAQ stock exchange.
The agreement includes a 40-day “go-shop” period during which ZimVie, with the assistance of its financial advisor Centerview Partners, may solicit alternative acquisition proposals from third parties. This period will continue through midnight, New York City time, on August 29, 2025. According to ZimVie, the company does not plan to disclose any developments in the process unless the Board of Directors decides to pursue a superior proposal.
Centerview Partners is serving as financial advisor to ZimVie, and Cravath, Swaine & Moore LLP is acting as legal advisor. ARCHIMED is being advised by UBS Investment Bank and legal counsel from Latham & Watkins LLP.
ZimVie Inc., based in Palm Beach Gardens, Florida, develops and manufactures dental implant technologies, biomaterials, and digital workflow solutions for tooth replacement and restoration procedures.
ARCHIMED is an investment firm with offices in Europe, North America, and Asia, focused exclusively on healthcare sectors including MedTech, biopharma products, diagnostics, and healthcare IT.
